Literature DB >> 16079837

Oncogene-induced senescence as an initial barrier in lymphoma development.

Melanie Braig1, Soyoung Lee, Christoph Loddenkemper, Cornelia Rudolph, Antoine H F M Peters, Brigitte Schlegelberger, Harald Stein, Bernd Dörken, Thomas Jenuwein, Clemens A Schmitt.   

Abstract

Acute induction of oncogenic Ras provokes cellular senescence involving the retinoblastoma (Rb) pathway, but the tumour suppressive potential of senescence in vivo remains elusive. Recently, Rb-mediated silencing of growth-promoting genes by heterochromatin formation associated with methylation of histone H3 lysine 9 (H3K9me) was identified as a critical feature of cellular senescence, which may depend on the histone methyltransferase Suv39h1. Here we show that Emicro-N-Ras transgenic mice harbouring targeted heterozygous lesions at the Suv39h1, or the p53 locus for comparison, succumb to invasive T-cell lymphomas that lack expression of Suv39h1 or p53, respectively. By contrast, most N-Ras-transgenic wild-type ('control') animals develop a non-lymphoid neoplasia significantly later. Proliferation of primary lymphocytes is directly stalled by a Suv39h1-dependent, H3K9me-related senescent growth arrest in response to oncogenic Ras, thereby cancelling lymphomagenesis at an initial step. Suv39h1-deficient lymphoma cells grow rapidly but, unlike p53-deficient cells, remain highly susceptible to adriamycin-induced apoptosis. In contrast, only control, but not Suv39h1-deficient or p53-deficient, lymphomas senesce after drug therapy when apoptosis is blocked. These results identify H3K9me-mediated senescence as a novel Suv39h1-dependent tumour suppressor mechanism whose inactivation permits the formation of aggressive but apoptosis-competent lymphomas in response to oncogenic Ras.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16079837     DOI: 10.1038/nature03841

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  490 in total

1.  PRAK suppresses oncogenic ras-induced hematopoietic cancer development by antagonizing the JNK pathway.

Authors:  Naoto Yoshizuka; Maoyi Lai; Rong Liao; Ryan Cook; Changchun Xiao; Jiahuai Han; Peiqing Sun
Journal:  Mol Cancer Res       Date:  2012-06-04       Impact factor: 5.852

2.  Dysfunction of nucleus accumbens-1 activates cellular senescence and inhibits tumor cell proliferation and oncogenesis.

Authors:  Yi Zhang; Yan Cheng; Xingcong Ren; Tsukasa Hori; Kathryn J Huber-Keener; Li Zhang; Kai Lee Yap; David Liu; Lisa Shantz; Zheng-Hong Qin; Suping Zhang; Jianrong Wang; Hong-Gang Wang; Ie-Ming Shih; Jin-Ming Yang
Journal:  Cancer Res       Date:  2012-06-04       Impact factor: 12.701

3.  Deregulation of oncogene-induced senescence and p53 translational control in X-linked dyskeratosis congenita.

Authors:  Cristian Bellodi; Noam Kopmar; Davide Ruggero
Journal:  EMBO J       Date:  2010-05-07       Impact factor: 11.598

Review 4.  Bypassing cellular senescence by genetic screening tools.

Authors:  Mar Vergel; Amancio Carnero
Journal:  Clin Transl Oncol       Date:  2010-06       Impact factor: 3.405

5.  WT1: a weak spot in KRAS-induced transformation.

Authors:  Silvia Licciulli; Joseph L Kissil
Journal:  J Clin Invest       Date:  2010-10-25       Impact factor: 14.808

6.  Oncogene-induced senescence results in marked metabolic and bioenergetic alterations.

Authors:  Celia Quijano; Liu Cao; Maria M Fergusson; Hector Romero; Jie Liu; Sarah Gutkind; Ilsa I Rovira; Robert P Mohney; Edward D Karoly; Toren Finkel
Journal:  Cell Cycle       Date:  2012-04-01       Impact factor: 4.534

7.  Global heterochromatin loss: a unifying theory of aging?

Authors:  Amy Tsurumi; Willis X Li
Journal:  Epigenetics       Date:  2012-07-01       Impact factor: 4.528

8.  Cellular senescence as a possible mechanism for halting progression of keloid lesions.

Authors:  Shohreh Varmeh; Ainara Egia; Duncan McGrouther; Steven R Tahan; Ardeshir Bayat; Pier Paolo Pandolfi
Journal:  Genes Cancer       Date:  2011-11

9.  Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal-like breast tumors.

Authors:  Mona L Gauthier; Hal K Berman; Caroline Miller; Krystyna Kozakeiwicz; Karen Chew; Dan Moore; Joseph Rabban; Yunn Yi Chen; Karla Kerlikowske; Thea D Tlsty
Journal:  Cancer Cell       Date:  2007-11       Impact factor: 31.743

Review 10.  Cell cycle, CDKs and cancer: a changing paradigm.

Authors:  Marcos Malumbres; Mariano Barbacid
Journal:  Nat Rev Cancer       Date:  2009-03       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.